These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24961498)

  • 21. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data.
    Yang X; Huang Y; Crowson M; Li J; Maitland ML; Lussier YA
    J Biomed Inform; 2010 Jun; 43(3):376-84. PubMed ID: 20434586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
    Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
    BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computational Approaches for the Design of (Mutant-)Selective Tyrosine Kinase Inhibitors: State-of-the-Art and Future Prospects.
    Kharkar PS
    Curr Top Med Chem; 2020; 20(17):1564-1575. PubMed ID: 32357816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors.
    Uitdehaag JC; de Roos JA; Prinsen MB; Willemsen-Seegers N; de Vetter JR; Dylus J; van Doornmalen AM; Kooijman J; Sawa M; van Gerwen SJ; de Man J; Buijsman RC; Zaman GJ
    Mol Cancer Ther; 2016 Dec; 15(12):3097-3109. PubMed ID: 27587489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In silico-in vitro discovery of untargeted kinase-inhibitor interactions from kinase-targeted therapies: A case study on the cancer MAPK signaling pathway.
    Meng L; Huang Z
    Comput Biol Chem; 2018 Aug; 75():196-204. PubMed ID: 29803964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
    Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
    Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
    Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
    Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Target Inhibition Maps Based on Responses to Kinase Inhibitors.
    Berlow N; Pal R
    Methods Mol Biol; 2017; 1636():507-522. PubMed ID: 28730499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.
    Ou O; Huppi K; Chakka S; Gehlhaus K; Dubois W; Patel J; Chen J; Mackiewicz M; Jones TL; Pitt JJ; Martin SE; Goldsmith P; Simmons JK; Mock BA; Caplen NJ
    Cancer Lett; 2014 Nov; 354(2):336-47. PubMed ID: 25193464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.
    Seashore-Ludlow B; Rees MG; Cheah JH; Cokol M; Price EV; Coletti ME; Jones V; Bodycombe NE; Soule CK; Gould J; Alexander B; Li A; Montgomery P; Wawer MJ; Kuru N; Kotz JD; Hon CS; Munoz B; Liefeld T; Dančík V; Bittker JA; Palmer M; Bradner JE; Shamji AF; Clemons PA; Schreiber SL
    Cancer Discov; 2015 Nov; 5(11):1210-23. PubMed ID: 26482930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
    J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.
    Artemov A; Aliper A; Korzinkin M; Lezhnina K; Jellen L; Zhukov N; Roumiantsev S; Gaifullin N; Zhavoronkov A; Borisov N; Buzdin A
    Oncotarget; 2015 Oct; 6(30):29347-56. PubMed ID: 26320181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells.
    Ctortecka C; Palve V; Kuenzi BM; Fang B; Sumi NJ; Izumi V; Novakova S; Kinose F; Remsing Rix LL; Haura EB; Koomen JM; Rix U
    Mol Cell Proteomics; 2018 Dec; 17(12):2434-2447. PubMed ID: 30217950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. K-Map: connecting kinases with therapeutics for drug repurposing and development.
    Kim J; Yoo M; Kang J; Tan AC
    Hum Genomics; 2013 Sep; 7(1):20. PubMed ID: 24060470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.
    Herberger B; Berger W; Puhalla H; Schmid K; Novak S; Brandstetter A; Pirker C; Gruenberger T; Filipits M
    Mol Cancer Ther; 2009 Jun; 8(6):1547-56. PubMed ID: 19509244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-content screening analysis of the p38 pathway: profiling of structurally related p38alpha kinase inhibitors using cell-based assays.
    Ross S; Chen T; Yu V; Tudor Y; Zhang D; Liu L; Tamayo N; Dominguez C; Powers D
    Assay Drug Dev Technol; 2006 Aug; 4(4):397-409. PubMed ID: 16945013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.
    Tadesse S; Bantie L; Tomusange K; Yu M; Islam S; Bykovska N; Noll B; Zhu G; Li P; Lam F; Kumarasiri M; Milne R; Wang S
    Br J Pharmacol; 2018 Jun; 175(12):2399-2413. PubMed ID: 28800675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.